

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



愛帝宮母嬰健康股份有限公司  
AIDIGONG MATERNAL & CHILD HEALTH LIMITED

*(Incorporated in Bermuda with limited liability)*

(Stock code: 286)

## PROFIT WARNING OF THE RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

This announcement is made by Aidigong Maternal & Child Health Limited (the “**Company**”, and together with its subsidiaries, collectively as the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, subject to its finalized unaudited condensed consolidated financial results for the six months ended 30 June 2022 (the “**Period**”), the Group expects to record a net loss of not more than HK\$65.00 million for the Period, while the Group recorded a net profit of HK\$27.06 million for the six months ended 30 June 2021 (the “**Same Period**”). The Group's net loss for the Period was mainly due to, among other things, (i) the phased epidemic control measures restricted the supply of postpartum care rooms for some centers, resulting in customers being unable to check in as scheduled. Despite good reservation status, the inability to realize revenue during the controlled period resulted in a decline in profit. At the same time, the new postpartum care centers opened in the second half of last year suffered losses which are still in the early stage of opening and in the process of growing the occupancy rate, thus eroding the profits of other existing centers and affecting the overall profits; (ii) during the Period, the financial expenses were approximately HK\$34.00 million, which were similar to the Same Period; (iii) compared to the Same Period, the Group did not have a gain on disposal of subsidiaries and associates which were HK\$27.27 million during the Same Period; (iv) non-cash expenses related to share award scheme for the Period amounted to approximately HK\$12.00 million; and (v) during the Period, the relevant residential health project has not yet been able to recognize the income from the sale of houses, while still incurring expenses.

The information contained in this announcement is only based on the preliminary assessment by the Board based on the information currently available to the Company, including the management accounts of the Group, which have neither been reviewed by the audit committee of the Company nor reviewed or audited by the external auditors of the Company. Further details of the Group's financial performance will be disclosed when the Company finalizes and announces its financial results for the Period, which is currently expected to be published on 31 August 2022.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Aidigong Maternal & Child Health Limited**  
**Zhu Yufei**  
*Chairman*

Hong Kong, 19 August 2022

*As at the date of this announcement, the Board comprises Ms. Zhu Yufei, Mr. Cheung Wai Kuen, Mr. Lin Jiang and Mr. Li Runping as executive Directors; and Ms. Yu Lin, Mr. Lam Chi Wing and Mr. Wong Yiu Kit, Ernest as independent non-executive Directors.*